Gday Babbanap. This is what we need. Stories
from the horses mouth. Not surprising that the
bloke you were talking to gained considerable
relief for his OA from stem cell. Sydney Uni is
conducting a large P3 trial currently using
IPSC (stem cells) for knee OA. Final evaluation/
readout expected first half 2026. Has the potential
to be major competitor for Zilosul.
IPPS and the most important membrane, page-11
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 40000 | 1 |
View Market Depth
| Last trade - 09.55am 06/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
Day chart unavailable